• NMPA has approved the registration of the iTrack™ Advance in China
• Nova Eye has an established, experienced channel partner in China
• Sales growth expected from late FY26

Nova Eye Medical Limited (ASX: EYE) has announced that the National Medical Products Administration (NMPA) has registered the iTrack™ Advance in China. This is a pivotal milestone in the company's strategy to expand global sales of its iTrack™ portfolio for the surgical treatment of glaucoma. The original iTrack™ device has been well accepted by Chinese surgeons, and the latest generation iTrack™ Advance offers significant improvements in surgical efficiency, which is expected to appeal to a broad cross-section of Chinese surgeons. This is expected to drive significant sales growth in the long term. The company's revenues generated from sales of the original iTrack™ device in China were US$1.2 million for the year ended 30 June 2025. Pre-launch initiatives with the company's exclusive channel partner in China will commence immediately, and sales growth is expected from late FY26 and beyond. Nova Eye Medical Managing Director, Tom Spurling, commented that the NMPA approval for iTrack™ Advance builds on the company's track record in China with the original iTrack™ device, and the established local sales partner is well positioned to drive the company's market access, sales, and marketing activities for the iTrack™ Advance. The milestone comes at a time when Chinese surgeons are being influenced by the paradigm shift toward interventional glaucoma, which is currently driving growth of the company's treatment technologies in the USA.

Sales growth is expected from late FY26 and beyond.